NCT00563836View on ClinicalTrials.gov

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

August 31, 2010

Conditions
Ovarian CancerEpithelial Ovarian Cancer
Interventions
DRUG

Catumaxomab

10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16

Trial Locations (2)

13355

Klinikum Charité, Berlin

Unknown

Innsbruck

Sponsors

Lead Sponsor

Neovii Biotech
All Listed Sponsors
lead

Neovii Biotech

INDUSTRY

NCT00563836 - Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter